-
Under the general trend of innovation, a number of new drugs have been introduced recently
Time of Update: 2022-08-10
, and further develop, register, manufacture and sell the target product zirconium Zr 89 crefmirlimab berdoxam in China For example, a few days ago, Dongcheng Pharmaceutical announced that its wholly-owned subsidiary Andico and ImaginAb, Inc. formally signed the "License Agreement".
-
The 100 million yuan purchase order has settled, Mindray, Neusoft, United Imaging...
Time of Update: 2022-08-10
994 million) Brand: Philips, Specification: ClearVue850, Quantity: 28 units, Unit price: 499,800 yuan; Subcontract 3 : Portable Color Doppler Ultrasound Diagnostic Instrument The first winning supplier : Nanjing Shangyi Trading Co.
-
Under the vigorous development of traditional Chinese medicine, the concentration of leading enterprises will increase
Time of Update: 2022-08-10
Marketing strategy, continuous increase in market investment and development coverage of terminal medical institutions, all three have achieved rapid growth in operating income Zuoli Pharmaceutical stated that, during the reporting period, based on the advantages of the three core products of Wuling Capsule, Bailing Tablet and Lingze Tablet being included in the National Essential Drug List, it adhered to the principle of "stable self-operation, strong investment promotion, cloth retail, and full modules".
-
The first company to evaluate the sodium gluconate of Shugeng, Oplinon added two new batches of generic drugs in April
Time of Update: 2022-08-10
, Ltd. 3 CYHS2200601 Doxorubicin Hydrochloride Liposome Injection Zhejiang Shengzhao Pharmaceutical Technology Co.
, Ltd. 3 CYHS2200601 Doxorubicin Hydrochloride Liposome Injection Zhejiang Shengzhao Pharmaceutical Technology Co.
, Ltd. 3 CYHS2200601 Doxorubicin Hydrochloride Liposome Injection Zhejiang Shengzhao Pharmaceutical Technology Co.
-
In 2022, a large number of pharmaceutical companies will accelerate their exit!
Time of Update: 2022-08-10
[Pharmaceutical Network Industry News] On May 17, the Jinan Administrative Examination and Approval Service Bureau issued an announcement on the cancellation of the "Drug Business License" (Retail) (No. 20220022), according to relevant regulations, including Shandong Zhiyaotang Pharmaceutical Chain Co.
-
Chia Tai Tianqing introduced it!
Time of Update: 2022-08-10
LAG3 mAb in Phase II clinical trials in ChinaInsight database Global rights and interests Insight database of LAG-3 monoclonal antibody Sym022 Global new drug module LAG-3 is the third immune checkpoint to achieve commercialization in the world after PD-1 and CTLA-4, and has been shown in PD-1 combination therapy Excellent curative effect .
-
Within 1 day, many executives of pharmaceutical companies resigned!
Time of Update: 2022-08-10
Celis Medical issued an announcement saying that the board of directors recently received a written resignation report submitted by the company's deputy general manager Huang Yongxi.
Celis Medical issued an announcement saying that the board of directors recently received a written resignation report submitted by the company's deputy general manager Huang Yongxi.
-
Pharmaceutical companies start a wave of cooperation again, and take the lead in the big health track!
Time of Update: 2022-08-10
The two parties will rely on their respective advantageous resources to jointly develop the big health business online and offline Imperial Palace Chain & Gome Holdings A few days ago, Imperial Palace Chain under Imperial Palace officially signed a strategic cooperation agreement with Oiyo, a subsidiary of Gome Holdings.
-
Multi-pharmaceutical companies have made progress in the clinical treatment of new drugs for breast cancer brain metastases!
Time of Update: 2022-08-10
. Not long ago, the online medical journal OncLive published data from the primary outcome analysis of the Phase II TUXEDO-1 trial evaluating the efficacy of Enhertu, a HER2-targeting antibody drug conjugate (ADC), in patients with HER2-positive breast cancer and active brain metastases.
-
Drug price adjustment has become the norm, and another batch of drugs has ushered in price reductions recently!
Time of Update: 2022-08-10
Click to enter the exhibition page Recently, the Wuhan Municipal Medical Insurance Bureau issued a notice to dynamically adjust the information of some drugs listed on the Internet, involving newly marketed drugs, patented drugs, drugs that are prone to shortage, over-rated generic drugs, common generic drugs, etc.
-
Pharmacy Review Express!
Time of Update: 2022-08-10
Lukang Pharmaceutical announced that its cefoxitin sodium for injection has passed the consistency evaluation of generic drugs .
Lukang Pharmaceutical announced that its cefoxitin sodium for injection has passed the consistency evaluation of generic drugs .
-
[Activated] The registration status of calcium hydrogen phosphate dihydrate is changed from "I" to "A"
Time of Update: 2022-08-10
25 original content the public Budenheim The registration number F20180000955 of calcium hydrogen phosphate dihydrate produced in Budenheim, Germany has now been activated, and the status has changed from "I" to "A" .
-
Reform of the review and approval system for drugs and medical devices: people's health needs review reform without stopping
Time of Update: 2022-08-10
The reporter learned that in order to encourage the research and development of innovative drugs and medical devices, the State Food and Drug Administration not only provides support in priority review and other aspects, but also formulates a series of "Technical Requirements for Pharmaceutical Common Issues in Application for Phase I Clinical Trials of Innovative Chemical Drugs", etc.
-
A number of local CRO pharmaceutical companies aim at overseas layouts, and the industry's internal volume continues to accelerate
Time of Update: 2022-08-10
[Pharmaceutical Network Industry News] Recently, the local CRO pharmaceutical company Pharmaron announced that the company signed an asset purchase agreement with Noramco in the United States to acquire the latter's API production base in Coventry, Rhode Island, United States.
-
Recently, a number of new drugs have ushered in new progress in the domestic market
Time of Update: 2022-08-10
Recently, a number of new products and indications have been approved for marketing At present, the speed of new drugs and medical devices at home and abroad is obviously accelerating in the domestic market.
-
The innovation of biopharmaceutical companies accelerated, and more than 90 companies completed financing in the first quarter
Time of Update: 2022-08-10
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for new drug research and development, promotion, At present, from the perspective of the industry as a whole, this wave of financing is still continuing.
-
Within a week, many pharmaceutical companies announced new personnel changes!
Time of Update: 2022-08-10
In general, changes in pharmaceutical executives are closely related to the company's strategy to deal with the market environment In 2021, there will be more frequent personnel changes in Tianjing Bio, including the former CEO Dr. Shen Huaqiong who announced that he will resign due to personal reasons.
-
The comprehensive seminar on the new water law of GB5749 for drinking water was successfully held!
Time of Update: 2022-08-10
The fresh review of 3part is here, check it out ↓ Part 1: At 14:00 on May 25, the comprehensive seminar on the new water method of drinking water GB5749-disinfection by-products Special guest: Director of the Water Office of the Environmental Institute of the Chinese Center for Disease Control and Prevention E Xueli, Chen Jie, Ion Chromatography Application Engineer at Thermo Fisher Scientific, and Zhang Tianyang, an associate professor at the School of Environmental Science and Engineering, Tongji University .
-
China Resources Sanjiu and Kunyao Group!
Time of Update: 2022-08-10
At the same time, in the face of the fact that the centralized procurement of proprietary Chinese medicines tends to be implemented, in recent years, the Kunming Pharmaceutical Group is trying to find a transformation path, and the out-of-hospital market has improved significantly .
-
Another domestic rare disease drug for children is about to be approved for marketing
Time of Update: 2022-08-10
At present, only imported products have been approved, and the domestic pharmaceutical company Zhongyuandong Bio is the exclusive application for generic listing vigabatrin powder is a highly effective drug for the treatment of infantile spasms.
